The B-cell–depleting drug rituximab was associated with a twofold increased risk for infection in patients with relapsing-remitting multiple sclerosis (RRMS), regardless of treatment duration or ...

Rituximab is linked to lower risks for renal complications than cyclophosphamide in adult patients with immunoglobulin A vasculitis.

LOS ANGELES, May 20 (Reuters) - Continued use of Rituxan cut by about 50 percent the risk that follicular lymphoma patients would have their cancer return, according to a late-stage study of the drug, ...

Although relapse rates were similar across all treatment categories, patients with GPA treated with rituximab monotherapy had a lower relapse risk relative to those on rituximab + cyclophosphamide ...

No patient in the 6-month rituximab group relapsed during the 24-month follow-up, and 1 patient in the 12-month group had a minor relapse. Tailored, risk-stratified rituximab regimens including yearly ...

Adding Adcetris (brentuximab vedotin) to Revlimid (lenalidomide) and Rituxan (rituximab) significantly improved survival and response rates versus Revlimid/Rituxan alone in relapsed/refractory diffuse ...

Combining Ixazomib With Subcutaneous Rituximab and Dexamethasone in Relapsed or Refractory Waldenström's Macroglobulinemia: Final Analysis of the Phase I/II HOVON124/ECWM-R2 Study Patients had ...

Truxima (rituximab-abbs) is a brand-name drug that’s prescribed for certain blood cancers, rheumatoid arthritis, and other conditions in adults. As with other drugs, Truxima can cause side effects, ...

Researchers report on the long-term immune changes in patients with refractory or relapsed chronic lymphocytic leukemia (CLL) treated with venetoclax and rituximab plus bendamustine and rituximab. The ...

Osaka, Japan – One monoclonal antibody, rituximab, can work wonders for the treatment of children with frequently relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome. However, what ...